๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 15 Shanghai 9 Guangzhou 6 Fuzhou 4 Hangzhou 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing15 Shanghai9 Guangzhou6 Fuzhou4 Hangzhou4
All 27 locations
Target enrolment
to

Trials with a site in Beijing

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
NCT07779018Lymphoma
Liping Dou
Phase 2
30
Beijing
2026-04-01
Recruiting
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
NCT07587840Lymphoma
Liping Dou
Phase 2
20
Beijing
2026-01-01
Recruiting
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
NCT07138547Lymphoma
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2025-12-26
Recruiting
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
NCT06895538Leukemia, MDS, Lymphoma
Peking University First Hospital
Phase 2/3
24
Beijing
2025-05-03
Active, closed
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
NCT07094477Lymphoma
Daihong Liu
Phase 2
50
Beijing
2025-04-01
Recruiting
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
NCT06971523Solid Tumor, Lymphoma
CytosinLab Therapeutics Co., Ltd.
Phase 1/2
224
Beijing
2024-12-25
Recruiting
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
NCT07155954Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
Peking University Third Hospital
Observational
779
Beijing
2024-10-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
NCT05948033Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Recruiting
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
NCT05631886Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
Chinese PLA General Hospital
Phase 1
10
Beijing
2023-07-04
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Recruiting
China Lymphoma Patient Registry Study
NCT03313271Lymphoma
Jun Zhu
Observational
5,000
Beijing
2017-05-17
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

12 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 15 studies
PhaseStudiesRecruitingShare
Phase 26340%
Phase 1/24426.7%
Observational2213.3%
Phase 1116.7%
Phase 2/3116.7%
Phase 3116.7%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Chinese PLA General Hospital33
Liping Dou22
AstraZeneca11
BeiGene10
CytosinLab Therapeutics Co., Ltd.11
Daihong Liu10
Hoffmann-La Roche11
Institute of Hematology & Blood Diseases Hospital, China11
Jun Zhu11
Peking University First Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.